Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Vomaris Wound Care, Inc.
Enhanced cellular migration1, electricidal impact on biofilms2-3 and economic efficacy data4-5 presented alongside expanded launch of Procellera Helix microcurrent-generating antimicrobial composite wound dressing line
TEMPE, Ariz., May 5, 2014 /PRNewswire/ -- Procellera® Technology – the world's only wireless microcurrent-generating, antimicrobial wound dressing was featured in twelve abstracts*, including one oral presentation at the recently held Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS) Spring 2014 conference in Orlando, Florida on April 25 – April 27. The abstracts reported the latest laboratory, clinical and health economic outcomes on Procellera Technology, a novel product that produces electrical fields through its matrix of embedded microcell batteries, manufactured by Vomaris Wound Care, Inc. The company also unveiled five new composite wound dressings featuring their signature microcurrent-generating technology and expanding their Procellera Helix™ portfolio.
Two of the abstracts highlighting cutting-edge translational research findings on Procellera Technology from Ohio State University were recipients of the "Excellence in Translational and Regenerative Science Award" awarded by the Wound Healing Society. Titled "Silver-Zinc Coupled Bioelectric Dressing Disrupts Bacterial Biofilm by Targeting Quorum Sensing and Antibiotic Resistance" and "A Redox Active Bioelectric Dressing Improves Human Keratinocyte Migration", these latest findings shed new light on the significant role Procellera's electrical fields play in epithelial cell repair and targeting bacterial biofilms.
"In our research, we were able to identify the physiologic mechanisms of action of a new bioelectric wound dressing and validate its merit in the care of patients. This is an excellent example of public-private collaboration between Ohio State and Vomaris Innovations, wherein we have combined our expertise in physical and biological sciences to advance wound care treatment options for patients at our comprehensive Wound Center" said Professor Chandan Sen, principal investigator and Director of the Comprehensive Wound Center at Ohio State University.
In two other abstracts of the twelve presented, authors concluded that Procellera Technology appeared to reduce healing time and improve wound closure rates4-5 when compared to other advanced treatment modalities, with findings pointing to significantly reduced cost. Consistently positive clinical outcomes were reported in multiple case studies of wounds of varying etiology including chronic wounds, dehisced surgical wounds, and complex wounds that had been refractory to healing prior to application of Procellera Technology.
The present state of health reform places highest value on interventions that not only improve quality but also decrease cost of care. In today's healthcare environment, new products that improve healing and minimize infection risk, such as Procellera Technology, may serve as an important wound care 'bridge" between gauze and expensive advanced bioengineered tissues, with the potential to reduce the burden of care in an efficient and cost-effective way.
"We have a rapidly growing body of clinical and economic data that continues to provide compelling evidence of the value of our technology, and strengthens our position in the wound care marketplace," commented Michael Nagel, President and CEO of Vomaris Innovations, Inc.
Procellera Technology creates an optimal healing environment; its microcurrent-generating technology promotes improved healing through enhanced cellular migration1 while simultaneously managing bioburden at the wound site. The expanded Procellera Helix composite wound dressing product portfolio adds high-performance adhesive and foam layers to its existing Procellera product line, and features an ultra-thin, lightweight design that flexes to maintain wound contact and optimize patient mobility. Its unique, anatomically designed ergonomic shapes conform easily to body contours, providing an ideal solution for orthopedic and foot and ankle surgical incision sites, scope and port sites, as well as partial and full thickness wounds.
"Procellera Helix offers the clinician a cutting-edge, intelligent line of dressings that provide targeted solutions to optimize healing and combat infections," added Nagel.
About Vomaris Wound Care, Inc.
Vomaris Wound Care, Inc., based in Tempe, Arizona, is a leading edge regenerative medical device company specializing in microcurrent field generating technologies for the wound care market. Its proprietary Procellera Technology is the world's only wireless, microcurrent-generating antimicrobial wound dressing. Procellera is indicated for professional (Rx), over-the-counter (OTC) and veterinary uses.
For more information, visit http://www.vomaris.com or call 480.921.4948.
*Procellera Technology abstracts presented at 2014 SAWC Spring:
©2012 PR Newswire. All Rights Reserved.